Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Protein Effect||no effect|
|Gene Variant Descriptions||Wild-type HRAS indicates that no mutation has been detected within the HRAS gene.|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|HRAS wild-type||melanoma||sensitive||E6201||Preclinical||Actionable||In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with wild-type HRAS (PMID: 23039341).||23039341|
|HRAS wild-type||cancer||predicted - sensitive||FTI-277||Preclinical||Actionable||In a preclinical study, the farnesyltransferase inhibitor FTI-277 sensitized Hras transformed rat fibroblasts to radiation therapy (PMID: 8620483).||8620483|
|HRAS wild-type||rhabdomyosarcoma||sensitive||Rigosertib||Preclinical - Cell culture||Actionable||In a preclinical study, Rigosertib (ON01910) inhibited cell viability and induced apoptosis in HRAS wild-type rhabdomyosarcoma cells in culture (PMID: 33158997).||33158997|
|Molecular Profile||Protein Effect||Treatment Approaches|
|HRAS wild-type||no effect|